JANUVIA® is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control.
For patients with type 2 diabetes mellitus in whom use of a PPARγ agonist (i.e. a thiazolidinedione) is appropriate, JANUVIA is indicated in combination with the PPARγ agonist when diet and exercise plus the PPARγ agonist alone, do not provide adequate glycaemic control.
This website is intended for healthcare professionals to find out more about the
clinical evidence behind JANUVIA.
If you are a healthcare professional, please enter your GMC or NMC number and
surname below to access the site.
|
| |
|
|
|
|
|
